drugset / Trial / NCT06745193
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of a combination treatment of chidamide, camrelizumab, and apatinib in patients with advanced esophageal cancer. This open-label, phase II clinical trial will involve randomly assigning participants to receive either the combination of these drugs or a standard treatment. The primary endpoints is ORR and the second endpoints include progression-free survival and overall survival, while safety will also be assessed.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2027-02-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |